Logo

Pfizer Receives the US FDA’s Approval of Talzenna (talazoparib) + Xtandi (enzalutamide) for the Treatment of Prostate Cancer

Share this
Pfizer

Pfizer Receives the US FDA’s Approval of Talzenna (talazoparib) + Xtandi (enzalutamide) for the Treatment of Prostate Cancer

Shots:

  • The US FDA has approved Talzenna + Xtandi for adult patients with HRR gene-mutated mCRPC. The approval was based on the P-III trial (TALAPRO-2) incl. 2 patient cohorts i.e., cohort 1 (all-comers; n=805) & cohort 2 (those with HRR (mutations; n=399) evaluating Talzenna + Xtandi vs PBO + Xtandi in 1125 patients
  • The results showed a 55% reduction in risk of disease progression or death with prospectively identified HRR gene mutations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C). The safety was consistent with the known safety profile of each therapy
  • Serious ARs (30%) & discontinuation of Talzenna (10%). The results from the (TALAPRO-2) cohort 1 were published in The Lancet while the final OS data is expected in 2024

Ref: Pfizer | Image: Pfizer

Related News:- Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions